Artículo de Revisión Referencias 1.- Czaja AJ. Diagnosis and management of 84 autoimmune hepatitis: current status and future directions. Gut Liver 2016; 10: 177-203. 2.- Manns MP, Lohse AW, Vergani D. Autoimmune hepatitis-Update 2015. J Hepatol 2015; 62: S1-S186. 3.- Heneghan MA, Yeoman AD, Verma S, Smith AD, Longhi MS. Autoimmune hepatitis. Lancet 2013; 382: 1433-44. 4.- Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006; 43 (Suppl. 1): S132- 44. 5.- Aizawa Y, Hokari A. Autoimmune hepatitis: Current challenges and future prospects. Clin Exp Gastroenterol 2017; 10: 9-18. 6.- Álvarez F, Berg PA, Bianchi FB, Burroughs AK, Cancado EL, Chapman RW, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38. 7.- Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76. 8.- Christen U, Hintermann E. Immunopathogenic mechanisms of autoimmune hepatitis: How much do we know from animal models. Int J Mol Sci 2016; 17: 2007. 9.- Zachou K, Muratori P, Koukoulis GK, Granito A, Gatselis N, Fabbri A, et al. Review article: autoimmune hepatitiscurrent management and challenges. Aliment Pharmacol Ther 2013; 38: 887- 913. 10.- Cropley A, Weltman M. The use of immunosuppression in autoimmune hepatitis: A current literature review. Clin Mol Hepatol 2017; 23: 22-6. 11.- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015; 63: 971-1004. 12.- Than NN, Jeffery HC, Oo YH. Autoimmune hepatitis: Progress from global immunosuppression to personalized regulatory T cell therapy. Canadian J Gastroenterol Hepatol 2016; 1-2. 13.- Mistilis SP, Vickers CR, Darroch MH, McCarthy SW. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust 1985; 143: 463-5. 14.- Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994; 21: 1040-7. Hepatitis autoi nmu ne refractaria - R. Zapata L . 15.- Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999; 94: 241-8. 16.- Ginesta A, Zapata R. Long term results of consecutive patients with steroid resistant chronic autoimmune hepatitis treated with cyclosporine. Ann Hepatology 2016; 15: 1011 (Abst). 17.- Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38: 805-9. 18.- Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Lowdose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007; 13: 3232-6. 19.- Than NN, Wiegard C, Weiler-Normann C, Füssel K, Mann J, Hodson J, et al. Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. Scand J Gastroenterol 2016; 51: 329-36. 20.- Zizzo AN, Valentino PL, Shah PS, Kamath BM. Second-Line Agents in Pediatric Patients with Autoimmune Hepatitis: A Systematic Review and Meta-Analysis. J Pediatr Gastroenterol Nutr 2017 Feb 4. Publicación electrónica en avance. 21.- Van Thiel DH, Wright H, Carroll P, Abu-Elmagd K, Rodríguez-Rilo H, McMichael J, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90: 771-6. 22.- Weiler-Normann C, Schramm C, Quaas A, Wiegard C, Glaubke C, Pannicke N, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol 2013; 58: 529-34. 23.- Burak KW, Swain MG, Santodomingo- Garzon T, Lee SS, Urbanski SJ, Aspinall AI, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol 2013; 27: 273-80. 24.- Chatrath H, Allen L, Boyer TD. Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am J Med 2014; 127: 1128-31. 25.- Ytting H, Larsen FS. Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use. Scand J Gastroenterol 2015; 50: 1025-31. 26.- Hübener S, Oo YH, Than NN, Hübener P, Weiler-Normann C, Lohse AW, Schramm C. Efficacy of 6-Mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance. Clin Gastroenterol Hepatol 2016; 14: 445-53. 27.- Wang Z, Sheng L, Yang Y, Yang F, Xiao X, Hua J, et al. The management of autoimmune hepatitis patients with decompensated cirrhosis: real-world experience and a comprehensive review. Clin Rev Allergy Immunol 2017; 52: 424-35. 28.- Montano-Loza AJ, Bhanji RA, Wasilenko S, Mason AL. Systematic review: recurrent autoimmune liver diseases after liver transplantation. Aliment Pharmacol Ther 2017; 45: 485-500. 29.- Ichai P, Duclos-Vallée JC, Guettier C, Hamida SB, Antonini T, Delvart V, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13: 996-1003. 30.- Zapata R, Ginesta A, Gómez F, Contreras J, Sanhueza E. Usefulness of cyclosporine as a rescue therapy for severe and fulminant forms of acute autoimmune hepatitis not responding to corticosteroids: A pilot study with long term results. Gastroenterology 2017; 152 (suppl 1); S1060-1. Gastroenterol. latinoam 2017; Vol 28, Nº 2: 76-84
gastrolat 2 2017
To see the actual publication please follow the link above